Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Oncology/Hematology Market Research

Lymphoma Therapeutics Market By Disease Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), By Treatment Type (Immune Therapy, Chemotherapy, Targeted Therapy, Radiation Therapy), By Route of Administration (Oral Route, Injectable), By Distribution Channel (Hos

Best Price Guarantee Length Publisher Published Date SKU
from $3,930 481 Pages Allied Market Research April, 2023 ALMR18022867
Best Price Guarantee
Price from $3,930
Length 481 Pages
Publisher Allied Market Research
Published Date April, 2023
SKU ALMR18022867

Lymphoma Therapeutics Market By Disease Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), By Treatment Type (Immune Therapy, Chemotherapy, Targeted Therapy, Radiation Therapy), By Route of Administration (Oral Route, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032


The Lymphoma Therapeutics Market is valued for $15,691.45 million in 2022 and is estimated to reach $35,207.45 million by 2032, exhibiting a CAGR of 8.4% from 2023 to 2032. Lymphoma is a type of cancer that affects the lymphatic system, which is a part of the immune system that helps to fight infections and other diseases. Lymphomas arise when certain types of white blood cells called lymphocytes undergo abnormal changes and begin to grow and multiply uncontrollably. Lymphoma therapeutics refers to various types of treatments that are used to treat lymphoma. Some of the various types of lymphoma therapeutics can include chemotherapy, radiation therapy, immunotherapy, targeted therapy, stem cell transplantation, and sometimes surgery.  

The key factor that drives the growth of the lymphoma therapeutics market is the growing pipeline of lymphoma therapeutics. For instance, according to GlobalData report in March 2023, larotrectinib sulfate by Bayer AG is under clinical development and currently in phase II for non-Hodgkin lymphoma. The phase II drugs for non-Hodgkin lymphoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into phase III.  

Moreover, significant rise in prevalence of lymphoma and surge in geriatric population notably contribute toward the growth of the market. Furthermore, increase in investment in R&D activities and favorable government policies for the approval of novel drugs to treat non-Hodgkin and Hodgkin lymphoma are expected to open new avenues for the growth of the global market during the forecast period.

However, the high cost of available treatments and lack of awareness about lymphoma and availability of different options to treat lymphoma among people hamper the market growth. Conversely, surge in geriatric population which is more susceptible to lymphoma and development of effective medicines that are accessible and safe for patients are expected to provide lucrative opportunity for the growth of the market during the forecast period.

The lymphoma therapeutics market is segmented into disease type, treatment type, route of administration, distribution channel, and region. By disease type, the market is bifurcated into Hodgkin lymphoma and non-Hodgkin lymphoma. On the basis of treatment type, it is fragmented into immune therapy, chemotherapy, targeted therapy, and radiation therapy. Depending on the route of administration, the market is categorized into oral route and injectables. As per distribution channel, it is segregated into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.  

North America garnered the maximum share of the lymphoma therapeutics market share in 2022 and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of non-Hodgkin lymphoma in the region and surge in awareness among the population regarding the available diagnostic technologies and treatment alternatives for lymphoma. Furthermore, availability of reimbursement policies and surge in number of clinical trials owing to rise in investment by key market players in R&D activities are expected to fuel the market growth.  

Asia-Pacific is expected to register the fastest CAGR during the forecast period owing to rise in geriatric population and strong pipeline of lymphoma drugs in developing countries. Furthermore, increase in prevalence of lymphoma and rise in awareness about treatment options available for lymphoma in the developing countries such as India, China, and South Korea contribute toward the growth of the market in this region.  

The key players that operate in the lymphoma therapeutics market are AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Eli Lily and Company, F Hoffman La Roche Ltd, Johnson & Johnson, Gilead Sciences, Inc., Seagen Inc., Teva Pharmaceutical Industries Ltd., and Pfizer Inc. 

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the lymphoma therapeutics market analysis from 2022 to 2032 to identify the prevailing lymphoma therapeutics market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the lymphoma therapeutics market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global lymphoma therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease Type

Hodgkin Lymphoma
Non-Hodgkin Lymphoma

By Treatment Type

Immune Therapy
Chemotherapy
Targeted Therapy
Radiation Therapy

By Route of Administration

Oral Route
Injectable

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Bayer AG
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
AstraZeneca
Pfizer Inc.
Bristol-Myers Squibb Company
Gilead Sciences, Inc.
Seagen Inc.

Please Note: It will take 7-10 business days to complete the report upon order confirmation.


CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in prevalence of lymphoma
3.4.1.2. Increase in number of drugs in pipeline
3.4.1.3. Rise in number of clinical trials
3.4.2. Restraints
3.4.2.1. High cost of available treatment
3.4.3. Opportunities
3.4.3.1. High growth potential in developing economies
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Hodgkin Lymphoma
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Non-Hodgkin Lymphoma
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Immune Therapy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Chemotherapy
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Targeted Therapy
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Radiation Therapy
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Oral Route
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Injectable
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital Pharmacies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Retail Pharmacies
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Online Pharmacies
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: LYMPHOMA THERAPEUTICS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key trends and opportunities
8.2.2. Market size and forecast, by Disease Type
8.2.3. Market size and forecast, by Treatment Type
8.2.4. Market size and forecast, by Route of Administration
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Key market trends, growth factors and opportunities
8.2.6.1.2. Market size and forecast, by Disease Type
8.2.6.1.3. Market size and forecast, by Treatment Type
8.2.6.1.4. Market size and forecast, by Route of Administration
8.2.6.1.5. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Key market trends, growth factors and opportunities
8.2.6.2.2. Market size and forecast, by Disease Type
8.2.6.2.3. Market size and forecast, by Treatment Type
8.2.6.2.4. Market size and forecast, by Route of Administration
8.2.6.2.5. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Key market trends, growth factors and opportunities
8.2.6.3.2. Market size and forecast, by Disease Type
8.2.6.3.3. Market size and forecast, by Treatment Type
8.2.6.3.4. Market size and forecast, by Route of Administration
8.2.6.3.5. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key trends and opportunities
8.3.2. Market size and forecast, by Disease Type
8.3.3. Market size and forecast, by Treatment Type
8.3.4. Market size and forecast, by Route of Administration
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Key market trends, growth factors and opportunities
8.3.6.1.2. Market size and forecast, by Disease Type
8.3.6.1.3. Market size and forecast, by Treatment Type
8.3.6.1.4. Market size and forecast, by Route of Administration
8.3.6.1.5. Market size and forecast, by Distribution Channel
8.3.6.2. France
8.3.6.2.1. Key market trends, growth factors and opportunities
8.3.6.2.2. Market size and forecast, by Disease Type
8.3.6.2.3. Market size and forecast, by Treatment Type
8.3.6.2.4. Market size and forecast, by Route of Administration
8.3.6.2.5. Market size and forecast, by Distribution Channel
8.3.6.3. UK
8.3.6.3.1. Key market trends, growth factors and opportunities
8.3.6.3.2. Market size and forecast, by Disease Type
8.3.6.3.3. Market size and forecast, by Treatment Type
8.3.6.3.4. Market size and forecast, by Route of Administration
8.3.6.3.5. Market size and forecast, by Distribution Channel
8.3.6.4. Italy
8.3.6.4.1. Key market trends, growth factors and opportunities
8.3.6.4.2. Market size and forecast, by Disease Type
8.3.6.4.3. Market size and forecast, by Treatment Type
8.3.6.4.4. Market size and forecast, by Route of Administration
8.3.6.4.5. Market size and forecast, by Distribution Channel
8.3.6.5. Spain
8.3.6.5.1. Key market trends, growth factors and opportunities
8.3.6.5.2. Market size and forecast, by Disease Type
8.3.6.5.3. Market size and forecast, by Treatment Type
8.3.6.5.4. Market size and forecast, by Route of Administration
8.3.6.5.5. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Key market trends, growth factors and opportunities
8.3.6.6.2. Market size and forecast, by Disease Type
8.3.6.6.3. Market size and forecast, by Treatment Type
8.3.6.6.4. Market size and forecast, by Route of Administration
8.3.6.6.5. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key trends and opportunities
8.4.2. Market size and forecast, by Disease Type
8.4.3. Market size and forecast, by Treatment Type
8.4.4. Market size and forecast, by Route of Administration
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Key market trends, growth factors and opportunities
8.4.6.1.2. Market size and forecast, by Disease Type
8.4.6.1.3. Market size and forecast, by Treatment Type
8.4.6.1.4. Market size and forecast, by Route of Administration
8.4.6.1.5. Market size and forecast, by Distribution Channel
8.4.6.2. China
8.4.6.2.1. Key market trends, growth factors and opportunities
8.4.6.2.2. Market size and forecast, by Disease Type
8.4.6.2.3. Market size and forecast, by Treatment Type
8.4.6.2.4. Market size and forecast, by Route of Administration
8.4.6.2.5. Market size and forecast, by Distribution Channel
8.4.6.3. Australia
8.4.6.3.1. Key market trends, growth factors and opportunities
8.4.6.3.2. Market size and forecast, by Disease Type
8.4.6.3.3. Market size and forecast, by Treatment Type
8.4.6.3.4. Market size and forecast, by Route of Administration
8.4.6.3.5. Market size and forecast, by Distribution Channel
8.4.6.4. India
8.4.6.4.1. Key market trends, growth factors and opportunities
8.4.6.4.2. Market size and forecast, by Disease Type
8.4.6.4.3. Market size and forecast, by Treatment Type
8.4.6.4.4. Market size and forecast, by Route of Administration
8.4.6.4.5. Market size and forecast, by Distribution Channel
8.4.6.5. South Korea
8.4.6.5.1. Key market trends, growth factors and opportunities
8.4.6.5.2. Market size and forecast, by Disease Type
8.4.6.5.3. Market size and forecast, by Treatment Type
8.4.6.5.4. Market size and forecast, by Route of Administration
8.4.6.5.5. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Key market trends, growth factors and opportunities
8.4.6.6.2. Market size and forecast, by Disease Type
8.4.6.6.3. Market size and forecast, by Treatment Type
8.4.6.6.4. Market size and forecast, by Route of Administration
8.4.6.6.5. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key trends and opportunities
8.5.2. Market size and forecast, by Disease Type
8.5.3. Market size and forecast, by Treatment Type
8.5.4. Market size and forecast, by Route of Administration
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Key market trends, growth factors and opportunities
8.5.6.1.2. Market size and forecast, by Disease Type
8.5.6.1.3. Market size and forecast, by Treatment Type
8.5.6.1.4. Market size and forecast, by Route of Administration
8.5.6.1.5. Market size and forecast, by Distribution Channel
8.5.6.2. Saudi Arabia
8.5.6.2.1. Key market trends, growth factors and opportunities
8.5.6.2.2. Market size and forecast, by Disease Type
8.5.6.2.3. Market size and forecast, by Treatment Type
8.5.6.2.4. Market size and forecast, by Route of Administration
8.5.6.2.5. Market size and forecast, by Distribution Channel
8.5.6.3. South Africa
8.5.6.3.1. Key market trends, growth factors and opportunities
8.5.6.3.2. Market size and forecast, by Disease Type
8.5.6.3.3. Market size and forecast, by Treatment Type
8.5.6.3.4. Market size and forecast, by Route of Administration
8.5.6.3.5. Market size and forecast, by Distribution Channel
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Key market trends, growth factors and opportunities
8.5.6.4.2. Market size and forecast, by Disease Type
8.5.6.4.3. Market size and forecast, by Treatment Type
8.5.6.4.4. Market size and forecast, by Route of Administration
8.5.6.4.5. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Bayer AG
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Bristol-Myers Squibb Company
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Eli Lilly and Company
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.3.7. Key strategic moves and developments
10.4. Johnson & Johnson
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Gilead Sciences, Inc.
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Seagen Inc.
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.6.7. Key strategic moves and developments
10.7. Teva Pharmaceutical Industries Ltd.
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.7.7. Key strategic moves and developments
10.8. Pfizer Inc.
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. AstraZeneca
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.9.7. Key strategic moves and developments
10.10. F. Hoffmann-La Roche Ltd.
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 02. LYMPHOMA THERAPEUTICS MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 03. LYMPHOMA THERAPEUTICS MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 05. LYMPHOMA THERAPEUTICS MARKET FOR IMMUNE THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 06. LYMPHOMA THERAPEUTICS MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 07. LYMPHOMA THERAPEUTICS MARKET FOR TARGETED THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 08. LYMPHOMA THERAPEUTICS MARKET FOR RADIATION THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 10. LYMPHOMA THERAPEUTICS MARKET FOR ORAL ROUTE, BY REGION, 2022-2032 ($MILLION)
TABLE 11. LYMPHOMA THERAPEUTICS MARKET FOR INJECTABLE, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GLOBAL LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 13. LYMPHOMA THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. LYMPHOMA THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 15. LYMPHOMA THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 16. LYMPHOMA THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 22. U.S. LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 23. U.S. LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 24. U.S. LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 25. U.S. LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. CANADA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 27. CANADA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 28. CANADA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 29. CANADA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 30. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 31. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 32. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 33. MEXICO LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 35. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 36. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 37. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. EUROPE LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 39. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 40. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 41. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 42. GERMANY LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 43. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 44. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 45. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 46. FRANCE LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. UK LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 48. UK LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 49. UK LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 50. UK LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ITALY LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 52. ITALY LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 53. ITALY LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 54. ITALY LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 55. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 56. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 57. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 58. SPAIN LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 59. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 60. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 61. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 64. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 68. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 69. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 70. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 71. JAPAN LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 72. CHINA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 73. CHINA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 74. CHINA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 75. CHINA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 76. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 77. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 78. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 79. AUSTRALIA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. INDIA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 81. INDIA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 82. INDIA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 83. INDIA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 84. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 85. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 90. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 92. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 93. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 94. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 95. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 96. LAMEA LYMPHOMA THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 97. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 98. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 99. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 100. BRAZIL LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 101. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 102. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 103. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 104. SAUDI ARABIA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 105. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 106. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 107. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 108. SOUTH AFRICA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 109. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 110. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 111. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 112. REST OF LAMEA LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 113. BAYER AG: KEY EXECUTIVES
TABLE 114. BAYER AG: COMPANY SNAPSHOT
TABLE 115. BAYER AG: PRODUCT SEGMENTS
TABLE 116. BAYER AG: PRODUCT PORTFOLIO
TABLE 117. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 118. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 119. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 120. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 121. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
TABLE 122. ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 123. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 124. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
TABLE 125. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 126. ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 127. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 128. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 129. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 130. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 131. GILEAD SCIENCES, INC.: KEY EXECUTIVES
TABLE 132. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 133. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
TABLE 134. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 135. GILEAD SCIENCES, INC.: KEY STRATERGIES
TABLE 136. SEAGEN INC.: KEY EXECUTIVES
TABLE 137. SEAGEN INC.: COMPANY SNAPSHOT
TABLE 138. SEAGEN INC.: PRODUCT SEGMENTS
TABLE 139. SEAGEN INC.: PRODUCT PORTFOLIO
TABLE 140. SEAGEN INC.: KEY STRATERGIES
TABLE 141. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 142. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 143. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 144. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 145. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
TABLE 146. PFIZER INC.: KEY EXECUTIVES
TABLE 147. PFIZER INC.: COMPANY SNAPSHOT
TABLE 148. PFIZER INC.: PRODUCT SEGMENTS
TABLE 149. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 150. PFIZER INC.: KEY STRATERGIES
TABLE 151. ASTRAZENECA: KEY EXECUTIVES
TABLE 152. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 153. ASTRAZENECA: PRODUCT SEGMENTS
TABLE 154. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 155. ASTRAZENECA: KEY STRATERGIES
TABLE 156. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 157. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 158. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 159. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 160. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. LYMPHOMA THERAPEUTICS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF LYMPHOMA THERAPEUTICS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN LYMPHOMA THERAPEUTICS MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALLYMPHOMA THERAPEUTICS MARKET
FIGURE 10. LYMPHOMA THERAPEUTICS MARKET, BY DISEASE TYPE, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR NON-HODGKIN LYMPHOMA, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. LYMPHOMA THERAPEUTICS MARKET, BY TREATMENT TYPE, 2022(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR IMMUNE THERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR CHEMOTHERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR TARGETED THERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR RADIATION THERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. LYMPHOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR ORAL ROUTE, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR INJECTABLE, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. LYMPHOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF LYMPHOMA THERAPEUTICS MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. LYMPHOMA THERAPEUTICS MARKET BY REGION, 2022
FIGURE 26. U.S. LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 27. CANADA LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 28. MEXICO LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 29. GERMANY LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 30. FRANCE LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 31. UK LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 32. ITALY LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 33. SPAIN LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 34. REST OF EUROPE LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 35. JAPAN LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)
FIGURE 36. CHINA LYMPHOMA THERAPEUTICS MARKET, 2022-2032 ($MILLION)<

$5,820
$3,930
$6,540
$9,870

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings